Biomarin Pharmaceutical Inc (BMRN) stock news · P/E 148, rev $3.22B
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
This BMRN news page leads with what Biomarin Pharmaceutical Inc filed — not a scraped headline mill.
No cached 8-K sentence for BMRN yet. We will not pad this page with generic market recap.
Latest reported BMRN revenue for 2025-12-31 was $3.22B. Net income was $348.9M. Revenue was up 12.9% from 2024-12-31 to 2025-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 147.7.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the BMRN stock page; for the tape open the quote page.
BMRN stock news FAQ
What are BMRN's latest revenue and net income?
Latest cached Biomarin Pharmaceutical Inc (BMRN) revenue for Dec 31, 2025 was $3.22B. Net income was $348.9M. Statements: https://lician.com/financials/bmrn
How did BMRN revenue change from the prior cached period?
Cached Biomarin Pharmaceutical Inc (BMRN) revenue was up 12.9% from $2.85B (Dec 31, 2024) to $3.22B (Dec 31, 2025). Statements: https://lician.com/financials/bmrn
What is BMRN's P/E ratio?
Biomarin Pharmaceutical Inc (BMRN) trailing P/E is 147.7 on the latest cached fundamentals snapshot.
What is BMRN's market cap?
Biomarin Pharmaceutical Inc (BMRN) market cap is $10.63B on the latest cached fundamentals snapshot.
What kind of company is BMRN?
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Where is BMRN stock news listed?
Cached stock news for Biomarin Pharmaceutical Inc (BMRN) is listed at https://lician.com/news/bmrn. Filings: https://lician.com/sec/bmrn
Not investment advice.